Physician profile
Huma Rohail
NPI 1164402335
$1,294.95
in general payments reported to CMS, 2019-2025
14 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $121 · 2021: $34.37 · 2022: $273 · 2023: $169 · 2024: $298 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612 · Education: $25.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.68 |
| Education | $25.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $215.31 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $170.96 | 2019-2022 | |
| Travere Therapeutics, INC. | $162.80 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $149.26 | 2021-2024 | Acthar |
| Vifor Pharma, INC. | $124.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.60 | 2022-2025 | |
| Alexion Pharmaceuticals, INC. | $103.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $58.65 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $51.56 | 2022-2024 | Lupkynis |
| Amgen INC. | $40.22 | 2023 | Tavneos |
| Lilly USA, LLC | $32.38 | 2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.45 | 2022 | |
| Ani Pharmaceuticals, INC. | $25.14 | 2022 | |
| Ardelyx, INC. | $21.46 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Huma Rohail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.